Tafasitamab Lenalidomide DLBCL Market

In the Tafasitamab Lenalidomide DLBCL Market, the largest therapy type share in 2026 is held by Monoclonal Antibody + Immunomodulator Combination Therapy, at 37.0%. The Tafasitamab + Lenalidomide segment leads by drug regimen with 42.4%. By line of therapy, 48.9% is attributed to Second-Line (2L).